Sanofi's vaccine unit – Sanofi Pasteur – is poised to launch new products that are expected to keep the business growing while the French pharma is in the midst of a business transition, with a new CEO at the helm. A quadrivalent high-dose influenza vaccine Fluzone is launching now, and the company hopes to launch its next-generation meningococcal vaccine MenQuadfi in April.
Sanofi Pasteur exec VP David Loew talked to Scrip in an interview in New York about the upcoming launches and the vaccines pipeline